97 related articles for article (PubMed ID: 15195173)
1. [Survival after high-dose therapy with autologous stem cell support].
Liseth K; Abrahamsen JF; Ekanger R; Nesthus I; Sjo MS
Tidsskr Nor Laegeforen; 2004 May; 124(10):1374-5. PubMed ID: 15195173
[TBL] [Abstract][Full Text] [Related]
2. [High dose chemotherapy with autologous stem cell support in cancer patients].
Abrahamsen JF; Kristoffersen EK; Hervig T; Ekanger R; Nesthus I; Ulvestad E
Tidsskr Nor Laegeforen; 2000 May; 120(13):1523-8. PubMed ID: 10916472
[TBL] [Abstract][Full Text] [Related]
3. [High-dose treatment with autologous stem cell support in a Norwegian region].
Hammerstrøm J; Aasland IL; Telhaug R; Moen T; Lødemel B; Sørum Y; Brudevold R; Herlofsen O; Sørbø JH; Almvik T; Lamvik J
Tidsskr Nor Laegeforen; 2004 Oct; 124(19):2498-500. PubMed ID: 15477890
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma.
Gertz MA; Wolf RC; Micallef IN; Gastineau DA
Bone Marrow Transplant; 2010 Sep; 45(9):1396-403. PubMed ID: 20062089
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
7. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens.
Ardeshna KM; Kakouros N; Qian W; Powell MG; Saini N; D'Sa S; Mackinnon S; Hoskin PJ; Goldstone AH; Linch DC
Br J Haematol; 2005 Aug; 130(3):363-72. PubMed ID: 16042685
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
9. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
10. [Autologous stem cell transplantation in haematological disorders,1980-2002].
Beckers MM; Verdonck LF; Cornelissen JJ; Schattenberg AV; Janssen JJ; Willemze R; van Imhoff GW; van der Lelie JH; Wijermans P; Schaafsma R; Baars J; van Marwijk Kooij MR; Biesma DH; van Biezen A; Brand R; Schouten HC
Ned Tijdschr Geneeskd; 2010; 154():A2025. PubMed ID: 20977803
[TBL] [Abstract][Full Text] [Related]
11. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
[TBL] [Abstract][Full Text] [Related]
12. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double blind comparative study of prophylactic parenteral nutritional support with or without glutamine in autologous stem cell transplantation for hematological malignancies -- three years' follow-up.
Sykorova A; Horacek J; Zak P; Kmonicek M; Bukac J; Maly J
Neoplasma; 2005; 52(6):476-82. PubMed ID: 16284692
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
[TBL] [Abstract][Full Text] [Related]
17. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
19. Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2x10(6) CD34+ cells/kg.
Abrahamsen JF; Wentzel-Larsen T; Bruserud O
Cytotherapy; 2004; 6(4):356-62. PubMed ID: 16146888
[TBL] [Abstract][Full Text] [Related]
20. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.
Qazilbash MH; Saliba R; De Lima M; Hosing C; Couriel D; Aleman A; Roden L; Champlin R; Giralt SA
Cancer; 2006 Mar; 106(5):1084-9. PubMed ID: 16456814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]